Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$15.33 USD
+0.18 (1.19%)
Updated Sep 25, 2024 03:59 PM ET
After-Market: $15.34 +0.01 (0.07%) 4:46 PM ET
2-Buy of 5 2
A Value A Growth D Momentum A VGM
Cash flow Statements
Fiscal Year End for Assembly Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -61.23 | -93.09 | -129.86 | -62.15 | -97.63 |
Depreciation/Amortization & Depletion | -1.14 | 0.65 | 42.69 | 0.68 | -1.24 |
Net Change from Assets/Liabilities | 76.34 | -2.12 | -11.40 | -30.31 | -9.53 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.76 | 10.10 | 5.17 | 28.83 | 24.34 |
Net Cash From Operating Activities | 22.74 | -84.46 | -93.40 | -62.96 | -84.07 |
Property & Equipment | -0.23 | -0.10 | -2.24 | -0.47 | -1.55 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -68.91 | 89.24 | 27.25 | 70.29 | -48.76 |
Other Investing Activities | 0.00 | 1.50 | 1.50 | -1.75 | 0.00 |
Net Cash from Investing Activities | -69.14 | 90.64 | 26.52 | 68.07 | -50.32 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 13.82 | 0.61 | 53.06 | 6.13 | 139.65 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 1.47 | 0.00 |
Net Cash from Financing Activities | 13.82 | 0.61 | 53.06 | 7.60 | 139.65 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -32.58 | 6.79 | -13.82 | 12.71 | 5.26 |
Cash at Beginning of Period | 52.42 | 45.63 | 59.44 | 46.73 | 41.47 |
Cash at End of Period | 19.84 | 52.42 | 45.63 | 59.44 | 46.73 |
Diluted Net EPS | -13.38 | -23.05 | -36.01 | -21.01 | -44.66 |
Fiscal Year End for Assembly Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -20.23 | -9.08 | -61.23 | -50.27 | -35.85 |
Depreciation/Amortization & Depletion | -2.16 | -1.23 | -1.14 | -0.17 | 0.03 |
Net Change from Assets/Liabilities | -15.36 | -9.15 | 76.34 | -7.16 | -5.97 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.29 | 1.10 | 8.76 | 6.69 | 4.73 |
Net Cash From Operating Activities | -35.47 | -18.36 | 22.74 | -50.90 | -37.06 |
Property & Equipment | -0.03 | -0.01 | -0.23 | -0.18 | -0.05 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 22.41 | 17.29 | -68.91 | 20.70 | 1.68 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 22.38 | 17.27 | -69.14 | 20.52 | 1.64 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 12.45 | 0.00 | 13.82 | 4.63 | 4.63 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 12.45 | 0.00 | 13.82 | 4.63 | 4.63 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -0.63 | -1.09 | -32.58 | -25.76 | -30.80 |
Cash at Beginning of Period | 19.84 | 19.84 | 52.42 | 52.42 | 52.42 |
Cash at End of Period | 19.21 | 18.75 | 19.84 | 26.66 | 21.62 |
Diluted Net EPS | -1.98 | -1.66 | -1.86 | -3.24 | -3.84 |